Trial · NCT06999343
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Forced expiratory volume in the first second (FEV1) | At inclusion and at 3-years follow-up | The amount of air expelled during the first second of a maximal expiration, performed after a maximal inspiration. |
| Primary | Carbon monoxide diffusion test (DLCO) | At inclusion and at 3-years follow-up | Pulmonary function test, in which the diffusion of gases through the pulmonary alveoli into the blood is studied. |
| Secondary | Age | Baseline | Years |
| Secondary | Sex at birth | Baseline | Male/Female |
| Secondary | Height | Baseline | Centimetres |
| Secondary | Weight | Baseline and at 1 year, 2 years and 3 years | Kg |
| Secondary | Smoking | Baseline | Cigarette packs/year |
| Secondary | The percentage of lung volume with emphysema measured on a chest CT scan. | At inclusion and at 3-years follow-up | |
| Secondary | 6-minute walk distance (6MWT) | Baseline and at 1 year, 2 years and 3 years | Metres in 6 minutes |
| Secondary | Grip strength with dynamometer | Baseline and at 1 year, 2 years and 3 years | Kg |
| Secondary | BODE Index | Baseline and month 6, 12, 18, 24, 30 and 36 | The BODE index will result in a score of zero to ten dependent upon FEV1, body-mass index, the distance walked in six minutes, and the modified MRC dyspnea scale where 0 is the best state of health and 10 is the worst. |
| Secondary | Dyspnoea | Baseline and at 1 year, 2 years and 3 years | 1, 2, 3, 4 or 5 grades where dyspnoea grade 1 is the best state of health and grade 5 is the worst state of health |
| Secondary | Major cardiovascular events | Month 6, 12, 18, 24, 30 and 36 | Select from a list (Myocardial infarction/new angina/stroke) if any of these events happen. |
| Secondary | Cancer events | Month 6, 12, 18, 24, 30 and 36 | Solid cancers Yes/No |
| Secondary | Renal dysfunction (microalbuminuria) | Month 6, 12, 18, 24, 30 and 36 | mg/g |
| Secondary | Concomitant treatment | Month 6, 12, 18, 24, 30 and 36 | EPOC concomitant treatment |
| Secondary | Exacerbations | Month 6, 12, 18, 24, 30 and 36 | YES/NO |
| Secondary | Emergency room visits | Month 6, 12, 18, 24, 30 and 36 | YES/NO |
| Secondary | Hospitalisations | Month 6, 12, 18, 24, 30 and 36 | YES/NO |
| Secondary | Intubation | Month 6, 12, 18, 24, 30 and 36 | YES/NO |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06999343/registered